Antithrombotic Activity of the Antiplatelet Agent Angipur on the Model of Arterial Thrombosis in Rats with Isoproterenol-Induced Myocardial Infarction

Bull Exp Biol Med. 2022 Jan;172(3):314-317. doi: 10.1007/s10517-022-05383-9. Epub 2022 Jan 10.

Abstract

We studied the effect of Angipur on the process of experimental thrombosis induced by damage to the carotid artery wall by surface application of 50% ferric chloride (III) solution in rats without comorbidities and with isoproterenol-induced myocardial infarction. In animals without comorbidities, Angipur administered intravenously was 1.2 times less effective, in terms of ED50, than the well-known inhibitor of GPIIb/IIIa platelet receptors tirofiban. However, under conditions of non-coronary myocardial infarction, Angipur significantly prolonged the time of thrombus formation and exhibited 1.4-fold higher activity than the reference drug tirofiban.

Keywords: Angipur; arterial thrombosis; isoproterenol-induced myocardial infarction; tirofiban.

MeSH terms

  • Animals
  • Fibrinolytic Agents / pharmacology
  • Fibrinolytic Agents / therapeutic use
  • Isoproterenol / adverse effects
  • Myocardial Infarction* / chemically induced
  • Myocardial Infarction* / drug therapy
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Glycoprotein GPIIb-IIIa Complex / adverse effects
  • Rats
  • Thrombosis* / chemically induced
  • Thrombosis* / drug therapy
  • Tyrosine

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • Isoproterenol